Radically improving cancer diagnostics
Our technology, superRCA, can detect 1 mutation in 100 000 wild-types
Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. The format and flexibility of the technology platform – and read-out based on flow cytometry – makes it suitable for research as well as clinical application.
Detect down to 1 mutation in 100 000 wild types. Because sensitivity matters.
Our services
Clinicians
Fast, reliable and ultrasensitive decision-making tools for improved cancer care.
Rarity Biosciences’ vision is to democratize cancer diagnostics by providing more accessible, patient-near laboratory analysis – based on a simple blood sample.
An ultrasensitive liquid biopsy assay can be analysed for all relevant mutations along with other blood works on existing instruments, in a laboratory near the practicing clinician.
superRCA is an ultra-sensitive and specific molecular amplification technology. It is used to detect very small amounts of DNA sequence variants, like cancer mutations, in patient tissue and blood samples.
Laboratories
Patient-near laboratory testing and read-out on established flow cytometry.
Rarity superRCA can expand the services of most hematology labs by providing highly-accurate, specialist cancer diagnostics, based on a simple blood test.
The Rarity superRCA assays are not only ultra-sensitive and multiplex, but fast and cost-efficient because they can be performed in a laboratory close to the treating clinician – on unused capacity of existing laboratory instrumentation.
Talk to us about partnering for patient-near specialist diagnostics and find out how you can expand your service offering without heavy investment.
Researchers
RUO kits and discovery panels for detecting rare nucleic acid sequences.
Rarity superRCA ultra-sensitive RUO kits allow you to detect and quantify extremely low amounts of nucleic acid sequences in tissue or blood samples.
We offer Ready-to-use RUO kits for AML, including probes, primers and preoptimized reagents, Designed RUO kits for targeted sequences for biomarker discovery at custom request and Collaboration and partnering at request.
Collaborate with us for clinical validation studies in AML, and to identify other clinical applications as well as for research and pharmaceutical development.
Ultrasensitive and reliable
10-100 times more sensitive than current technology. Detects 1 mutation in 100 000
Multiplex but simple
Run tests on up to multiple targets simultaneously. Analyze by established flow cytometry
Fast & cost-efficient
Patient-near testing on existing equipment for fast results and better patient outcomes
